Naibec Verifies Efficacy of Capsule Treatment for Inflammatory Bowel Disease... Potential Fundamental Therapy with Peptide Treatment

Joint Research with UK InterectPharma
Oral Formulation and Animal Efficacy Verification of Inflammatory Bowel Disease Treatment Completed
Expecting Momentum in Related Discussions with Global Pharmaceutical Companies

[Asia Economy Reporter Hyungsoo Park] Naivek, a peptide fusion bio-specialized company, has succeeded in developing and verifying the efficacy of an oral colon-targeted formulation for the treatment of inflammatory bowel disease (IBD). Since the oral formulation was developed for clinical use, clinical trials are expected to accelerate following this development milestone.

Naivek announced on the 14th that it has successfully completed the design of an oral capsule formulation targeting the colon and pharmacokinetic studies in animals for ‘NIPEP-IBD,’ a peptide therapeutic for inflammatory bowel disease jointly developed with the UK biotech company ‘Intract Pharma.’

This success in developing an oral formulation applicable to humans beyond animal testing means that global clinical trials can now proceed. With the finalization of the NIPEP-IBD oral formulation, Naivek has begun preparations for overseas clinical trial applications in collaboration with global contract research organizations (CROs).

Under a joint research agreement, Naivek has supplied Intract Pharma with NIPEP-IBD, a ‘top discovery peptide’-based candidate drug for colon-targeted inflammatory bowel disease treatment. Intract Pharma was responsible for optimizing the oral formulation of NIPEP-IBD and verifying its efficacy in animal models.

Existing treatments for inflammatory bowel disease have focused solely on anti-inflammatory effects, lacking fundamental therapeutic efficacy. Naivek’s NIPEP-IBD is a novel peptide therapeutic that not only suppresses inflammation but also promotes regeneration and healing of the intestinal mucosa, enabling more fundamental treatment.

Drugs based on the ‘Janus kinase (JAK) inhibitor’ currently under development have failed to achieve clinical success due to concerns over side effects. In contrast, NIPEP-IBD demonstrates excellent regenerative effects, attracting interest from global pharmaceutical companies, with active discussions underway. The completion of the oral formulation development is expected to further accelerate negotiations with global pharmaceutical firms.

A Naivek representative stated, "Naivek has strengths in formulation design using peptides," adding, "Following the development of the oral formulation for inflammatory bowel disease treatment, we plan to expand its application to other peptide therapeutics to enhance patient medication convenience."

He continued, "The oral formulation is sufficiently effective with once-daily administration," and explained, "The capsule does not dissolve in the stomach or small intestine but only in the colon, where it binds to biomarkers of the damaged intestinal mucosa to exert regenerative effects, making it more effective than injectable formulations."

He also added, "We have started discussions with overseas CROs to enter global Phase 1 clinical trials for the inflammatory bowel disease treatment," and stated, "Our goal is to simultaneously conduct Phase 1 and Phase 2a clinical trials next year."

Naivek possesses efficient drug delivery technology utilizing a peptide platform. It can apply formulations that maximize drug efficacy, including injectable, oral, and inhalation formulations, enabling the development of therapeutics that consider patient ease of drug administration.

This content was produced with the assistance of AI translation services.